Biologics in psoriasis: can they prevent joint involvement?

Ms Kathleen Miao

Home > Dermatology > AAD 2023

Read the full Report (pdf)

American Academy of Dermatology 17–21 March 2023 New Orleans, USA

Featured articles

Letter from the Editor

Editor

Prof. Peter van de Kerkhof, Radboud University, the Netherlands

Conference

AAD 2023

11 May, 2023 16:48

AAD 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

AAD 2023

4 April, 2023 23:46

Online First

New Developments in Dermatology

Delgocitinib shows promise as topical therapy for chronic hand eczema

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, DELTA 1

Conference

AAD 2023

15 May, 2023 10:58

Vitiligo patients maintain re-pigmentation after ruxolitinib cream withdrawal

Presented By

Prof. John Harris, UMass Chan Medical School, MA, USA

Conference

AAD 2023

15 May, 2023 10:51

Nemolizumab decreases lesions and itch in prurigo nodularis

Presented By

Prof. Shawn Kwatra , Johns Hopkins University School of Medicine, MD, USA

Trial

Phase 3, OLYMPIA 2

Conference

AAD 2023

15 May, 2023 10:40

Lichen planus: a future indication for baricitinib?

Presented By

Ms Angelina Hwang , Mayo Clinic College of Medicine, AZ, USA

Trial

Phase 2

Conference

AAD

15 May, 2023 09:58

Atopic Dermatitis: State of the Art

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, TRuE-AD1 and TRuE-AD2

Conference

AAD 2023

15 May, 2023 11:43

Dupilumab: a viable option for atopic hand and foot eczema

Presented By

Prof. Eric Simpson, Oregon Health & Science University, OR, USA

Trial

Phase 3, LIBERTY-AD-HAFT

Conference

AAD 2023

15 May, 2023 11:33

Topical roflumilast beneficial in atopic dermatitis

Presented By

Prof. Lawrence Eichenfield, University of California San Diego, CA, USA

Trial

Phase 3, INTEGUMENT-1 and INTEGUMENT-2

Conference

AAD 2023

15 May, 2023 11:27

IL-22 receptor blocker reduces itch and skin lesions in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 2

Conference

AAD 2023

15 May, 2023 11:17

Psoriasis: New Developments

Switching to risankizumab successful in IL-17 inhibitor non-responders

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, aIMM study

Conference

AAD 2023

15 May, 2023 11:56

Novel, selective TYK2 inhibitor shows promise for psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine of University of California, LA, USA

Trial

Phase 2

Conference

AAD 2023

15 May, 2023 11:51

Hidradenitis Suppurativa: What You Need to Know

Izokibep shows remarkably high grades of clinical response in HS

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3

Conference

AAD 2023

15 May, 2023 12:31

Bimekizumab could be the new up-and-comer for HS treatment

Presented By

Prof. Alexa Kimball, Harvard Medical School, MA, USA

Trial

Phase 3, BE HEARD I and BE HEARD II

Conference

AAD 2023

15 May, 2023 12:26

Pearls of the Posters